Dr. Staudt pioneered the use of gene expression profiling to discover molecularly and clinically distinct cancer subtypes and to predict response to therapy. He defined molecular subtypes of lymphoma that were previously unrecognized but are now viewed as distinct diseases that arise from different stages of B-cell differentiation, utilize different oncogenic mechanisms, and offer new therapeutic targets. To develop new treatments for lymphoid malignancies, Dr. Staudt’s laboratory uses various high-throughput approaches, including cancer gene resequencing, RNAi/CRISPR-based genetic screens, and combinatorial small molecule screens. The laboratory also conducts genomic investigations within therapeutic trials of targeted agents in lymphoma to define mechanisms of response and resistance.

Dr. Staudt is currently Co-Chief of the NCI Lymphoid Malignancies Branch and Director of the NCI Center for Cancer Genomics (CCG) which encompasses several projects including GDC. He has received numerous awards for his research, including the 2009 Dameshek Prize from the American Society of Hematology for outstanding contribution in hematology and election to the National Academy of Sciences in 2013.